title: [French data from the Continuing to Confront COPD (C2C) survey].
abstract: BACKGROUND
  This article describes the French data which contributed to the international "Continuing to Confront COPD" (C2C) survey conducted in 2013 across 12 countries. Its objective was to describe the characteristics, symptoms and impact of COPD on health status, daily activities and working life in adults identified with the study definition as COPD; i.e., reporting a diagnosis of COPD, emphysema, chronic bronchitis (CB) or symptoms of CB either currently present or for which they had been treated in the past.
  
  
  METHODS
  Subjects 40 years or older were screened using random-digit-dialing and those fulfilling the study COPD definition were invited to complete the full survey.
  
  
  RESULTS
  The proportion of respondents with COPD (according to study definition) in France was estimated at 7.5%. Among 300 respondents with COPD and complete questionnaire data, 48% were male, 44% aged over 70years, 45% were overweight and 72% had a smoking history. COPD had a severe or very severe impact (COPD assessment test score>20) on health for 43%. Dyspnea (mMRC ≥ 1) was reported by 70% and a limitation of at least 20% of daily activities by 65%. The mean number of exacerbations was 2/year and 16% had been admitted to hospital for respiratory problems during the past year. However, using direct questions, 80% subjects considered that they had mild to moderately severe disease and 78% reported an acceptable health status.
  
  
  CONCLUSIONS
  The impact of COPD is markedly underestimated by respondents with COPD despite a high level of symptoms, poor health status and frequent exacerbations as assessed with validated measures.
authors.affiliation: Service de pneumologie et réanimation, AP-HP groupe hospitalier Hôtel-Dieu et université Paris Descartes, 74, boulevard de Port-Royal, 75004 Paris, France. Electronic address: nicolas.roche@aphp.fr.
authors.forename: N
authors.initials: N
authors.lastname: Roche
authors.affiliation: GlaxoSmithKline, 100, route de Versailles, 78160 Marly-le-Roi, France.
authors.forename: R
authors.initials: R
authors.lastname: Ajjouri
authors.affiliation: GlaxoSmithKline, 100, route de Versailles, 78160 Marly-le-Roi, France.
authors.forename: A
authors.initials: A
authors.lastname: Compagnon
authors.affiliation: Centre médical de l'université de Groningen, université de Groningen, Groningen, Pays-Bas.
authors.forename: T
authors.initials: T
authors.lastname: Van Der Molen
authors.affiliation: GlaxoSmithKline Research & Development, Respiratory Epidemiology, Uxbridge, Royaume-Uni.
authors.forename: H
authors.initials: H
authors.lastname: Mullerova
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015897:Comorbidity; D018450:Disease Progression; D005260:Female; D005602:France / Q000453:epidemiology; D006304:Health Status; D006306:Health Surveys; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000453:epidemiology* / Q000473:pathology*; D011788:Quality of Life; D012720:Severity of Illness Index; D012959:Socioeconomic Factors
keywords: BPCO; COPD; Epidemiology; Exacerbations; Hospitalisations; Hospitalizations; Prevalence; Prévalence; Épidémiologie